Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jul 13:15:31086.
doi: 10.34172/bi.31086. eCollection 2025.

Targeting immune checkpoints as a new therapeutic strategy for intra-hepatic cholangiocarcinoma

Eman G Khedr  1 , Mariam A Abo Seif  1 , Othman F Abdelzaher  2 , Ahmed B M Mehany  2 , Ola A El-Feky  1
Affiliations

Targeting immune checkpoints as a new therapeutic strategy for intra-hepatic cholangiocarcinoma

Eman G Khedr et al. Bioimpacts. .

Abstract

Introduction: Intrahepatic cholangiocarcinoma (IH-CCA) is a malignancy characterized with limited response to standard chemotherapeutic strategies due to development of drug resistance. We aim to investigate new immune-therapeutic strategy through using AUNP-12 as an immune checkpoint blocker in chemically induced IH-CCA mice model.

Methods: Mice were randomly divided into 2 groups; normal control group and disease group. The disease group was further subdivided into 5 subgroups assigned according to treatment modality. The Immunotherapeutic mechanism of AUNP-12 was investigated through analysis of PD-1/PD-L1 levels and IFN-γ Levels in the tumor microenvironment. Immunohistochemical analysis of CD3+T lymphocytes and TGF-β was performed.

Results: We reported that AUNP-12 significantly decreased levels of PD-1/PD-L1 at the site of tumor with subsequent activation of CD3+T lymphocytes that secrete IFN-γ which specifically lysis tumor cells. AUNP-12 also acts through downregulation of TGF-β signaling in IH-CCA mice group treated with AUNP-12.

Conclusion: Our data indicated that AUNP-12 effectively harbors IH-CCA progression and improves the survival rate of mice. AUNP-12 acts as an immune check point blocker that specifically inhibits PD-1/PD-L1 binding, activates cytotoxic T-lymphocytes, and downregulates TGF-β signaling pathway.

Keywords: Apoptosis; Immune checkpoint blockade; Intra-hepatic cholangiocarcinoma; PD-1/PD-L1; d-Peptide.

PubMed Disclaimer

Conflict of interest statement

No potential conflict of interest relevant to this article was reported.

Figures

Fig. 1
Fig. 1
Fig. 2
Fig. 2
Fig. 3
Fig. 3
Fig. 4
Fig. 4
Fig. 5
Fig. 5
Fig. 6
Fig. 6
Fig. 7
Fig. 7
See this image and copyright information in PMC

References

    1. Brindley PJ, Bachini M, Ilyas SI, Khan SA, Loukas A, Sirica AE, et al. Cholangiocarcinoma. Nat Rev Dis Primers. 2021;7:65. doi: 10.1038/s41572-021-00300-2. - DOI - PMC - PubMed
    1. Sarcognato S, Sacchi D, Fassan M, Fabris L, Cadamuro M, Zanus G, et al. Cholangiocarcinoma. Pathologica. 2021;113:158–69. doi: 10.32074/1591-951x-252. - DOI - PMC - PubMed
    1. Chen W, Hu Z, Song J, Wu Y, Zhang B, Zhang L. The state of therapy modalities in clinic for biliary tract cancer. Front Biosci (Landmark Ed) 2022;27:185. doi: 10.31083/j.fbl2706185. - DOI - PubMed
    1. Christodoulou MI, Zaravinos A. New clinical approaches and emerging evidence on immune-checkpoint inhibitors as anti-cancer therapeutics: CTLA-4 and PD-1 pathways and beyond. Crit Rev Immunol. 2019;39:379–408. doi: 10.1615/CritRevImmunol.2020033340. - DOI - PubMed
    1. Davenport AP, Scully CCG, de Graaf C, Brown AJH, Maguire JJ. Advances in therapeutic peptides targeting G protein-coupled receptors. Nat Rev Drug Discov. 2020;19:389–413. doi: 10.1038/s41573-020-0062-z. - DOI - PubMed

LinkOut - more resources